Cargando…
Recent Advances in the Management of Adverse Events Associated with Lorlatinib
As a novel third-generation ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown excellent systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations and progress on first- and second-generation TKIs. In comparison with other...
Autores principales: | Liao, Dehua, Zhang, Jiwen, Yan, Ting, Chen, Shanshan, Li, Wei, Shangguan, Dangang, She, Zhihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492578/ https://www.ncbi.nlm.nih.gov/pubmed/37694103 http://dx.doi.org/10.2147/OTT.S426989 |
Ejemplares similares
-
Podcast on the Management of Adverse Events Associated with Lorlatinib
por: Bauer, Todd M., et al.
Publicado: (2022) -
Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer
por: Liao, Dehua, et al.
Publicado: (2022) -
Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments
por: Chen, Shanshan, et al.
Publicado: (2023) -
Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners
por: Reed, Mollie, et al.
Publicado: (2020) -
Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib
por: Blais, Normand, et al.
Publicado: (2021)